Cross-Platform Evaluation of Commercial Metabolomics Platforms to Support Precision Therapeutics Research

As part of its RAPID-DxTM (Research Alliance for Precision Therapeutics, Innovation and Diagnostics) program, researchers from Cohen Veterans Bioscience (CVB) and collaborators conducted a blinded cross-platform analysis (or "bakeoff") of commercially available assay platforms to inform selection in the conduct of neuropsychiatric biomarker research.

Share this article:

More from CVB

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/07/CVB-CVN-allyson-quote-square.jpg

Cohen Veterans Network Publishes White Paper Providing Recommendations for Measurement-Based Mental Health Care

https://www.cohenveteransbioscience.org/wp-content/uploads/2023/05/CVB-PR_MM-matt_mitchell_quote-1200x670-2.jpg

Cohen Veterans Bioscience Joins Veteran Matthew Mitchell on Military Makeover with Montel to Discuss Traumatic Brain Injury

https://www.cohenveteransbioscience.org/wp-content/uploads/2022/11/cvb-22-jumps-2.jpg

Cohen Veterans Bioscience and 22 Jumps Announce Parachuting with Purpose: Recognizing the Epidemic of Veterans Suicide as a Result of Traumatic Brain Injury (TBI) and PTSD

About Cohen Veterans Bioscience (CVB)

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

For Media Inquiries

Please feel free to email us at media@cohenbio.org